T2D individuals treated with SGLT2i demonstrate improved glycemic control, increased glucose- and incretin-stimulated insulin secretion and enhanced insulin sensitivity as well as reduced blood pressure, decreased plasma lipids and reduced risk for cardiovascular events [21–24]. This evidence concerns the gene GCG and type 2 diabetes mellitus.